These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37422330)

  • 21. A review of emerging factor XI inhibitors.
    Elsheikh S; Tidbury N; Lip GYH
    Expert Opin Emerg Drugs; 2023 Mar; 28(1):43-53. PubMed ID: 36927160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of factor XIa as a new approach to anticoagulation.
    Schumacher WA; Luettgen JM; Quan ML; Seiffert DA
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):388-92. PubMed ID: 20139363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coagulation factor XI as a novel target for antithrombotic treatment.
    Löwenberg EC; Meijers JC; Monia BP; Levi M
    J Thromb Haemost; 2010 Nov; 8(11):2349-57. PubMed ID: 20727068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new strategy for anticoagulation: The factor XI inhibitors.
    Vedovati MC; Becattini C; Agnelli G
    Eur J Intern Med; 2023 Oct; 116():8-15. PubMed ID: 37544845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evidence-based research and prognosis of novel coagulation factor Ⅺ inhibitors in venous thromboembolism].
    Liu D; Tian H; Zhai ZG
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Sep; 45(9):925-930. PubMed ID: 36097930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors.
    Salomon O; Gailani D
    J Thromb Haemost; 2022 Jan; 20(1):32-38. PubMed ID: 34735741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorescent Activity-Based Probe To Image and Inhibit Factor XIa Activity in Human Plasma.
    Modrzycka S; Kołt S; Adams TE; Potoczek S; Huntington JA; Kasperkiewicz P; Drąg M
    J Med Chem; 2023 Mar; 66(6):3785-3797. PubMed ID: 36898159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation.
    Barnes GD; Ageno W; Castellucci LA; Chiasakul T; Eslick R; Ferreiro JL; Gailani D; Gorog DA; Lip GYH; Raffini L; Rezende SM; Weitz JI; Cuker A
    J Thromb Haemost; 2023 May; 21(5):1381-1384. PubMed ID: 36796485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factor XI and contact activation as targets for antithrombotic therapy.
    Gailani D; Bane CE; Gruber A
    J Thromb Haemost; 2015 Aug; 13(8):1383-95. PubMed ID: 25976012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders.
    Campello E; Simioni P; Prandoni P; Ferri N
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The rebirth of the contact pathway: a new therapeutic target.
    Srivastava P; Gailani D
    Curr Opin Hematol; 2020 Sep; 27(5):311-319. PubMed ID: 32740037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.
    Heitmeier S; Visser M; Tersteegen A; Dietze-Torres J; Glunz J; Gerdes C; Laux V; Stampfuss J; Roehrig S
    J Thromb Haemost; 2022 Jun; 20(6):1400-1411. PubMed ID: 35289054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review.
    Prakash S; Mares AC; Porres-Aguilar M; Mukherjee D; Barnes GD
    Vasc Med; 2024 Feb; 29(1):85-92. PubMed ID: 37947131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of the Potential Clinical Benefits of Small Molecule Factor XIa Inhibitors in Arterial Thrombosis.
    Wichaiyo S; Parichatikanond W; Visansirikul S; Saengklub N; Rattanavipanon W
    ACS Pharmacol Transl Sci; 2023 Jul; 6(7):970-981. PubMed ID: 37470020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials.
    DeLoughery EP; Olson SR; Puy C; McCarty OJT; Shatzel JJ
    Semin Thromb Hemost; 2019 Jul; 45(5):502-508. PubMed ID: 31216587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism.
    Cohen O; Ageno W
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):495-505. PubMed ID: 36485148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors.
    Chan NC; Weitz JI
    Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):1755-1763. PubMed ID: 37650326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor XI inhibitors: what should clinicians know.
    Pandey A; Verma R; Eikelboom J; Verma S
    Curr Opin Cardiol; 2023 Mar; 38(2):88-93. PubMed ID: 36718618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticoagulant therapy in patients with congenital FXI deficiency.
    Bravo-Pérez C; Serna MJ; Esteban J; Fernandez-Mellid E; Fontanes-Trabazo E; Lorenzo A; Calviño-Suárez M; Miñano A; Padilla J; Roldán V; Vicente V; Corral J; de la Morena-Barrio ME
    Blood Adv; 2021 Oct; 5(20):4083-4086. PubMed ID: 34597376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coagulation factors XI and XII as possible targets for anticoagulant therapy.
    Kluge KE; Seljeflot I; Arnesen H; Jensen T; Halvorsen S; Helseth R
    Thromb Res; 2022 Jun; 214():53-62. PubMed ID: 35490644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.